Eli Lilly and Company $LLY Shares Sold by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 34.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,539 shares of the company’s stock after selling 1,340 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Eli Lilly and Company were worth $2,287,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Osbon Capital Management LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $30,000. Maseco LLP lifted its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. grew its stake in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LLY. Leerink Partners increased their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Finally, Morgan Stanley boosted their price target on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor interest remains strong in Eli Lilly thanks to its leadership in the fast-growing weight-loss and GLP-1 drug market, which continues to support long-term growth expectations.
• Positive Sentiment: Articles highlighting a possible stock split suggest shares trading above $1,000 could make LLY more accessible to retail investors and keep demand elevated.
• Positive Sentiment: Erste Group Bank issued an optimistic earnings estimate for LLY, reinforcing confidence in the company’s strong profit outlook.
• Neutral Sentiment: Coverage describing Eli Lilly as a trending stock shows the name remains heavily watched, which can amplify moves but does not by itself change fundamentals.
• Neutral Sentiment: Several valuation-focused articles argue the stock looks expensive or fully valued after its massive multi-year rally, suggesting expectations are already high.
• Neutral Sentiment: News about Eli Lilly’s $3.8 billion psychedelic-medicine deal and commentary around the ATAI buyout are more about strategic expansion than immediate revenue impact.
• Negative Sentiment: Recent commentary that LLY may be fully valued, stretched, or expensive has likely added to profit-taking pressure after the stock’s strong advance.
• Negative Sentiment: One market recap noted Eli Lilly fell more than the broader market in the latest session, reflecting a weaker short-term trading tone.

Eli Lilly and Company Stock Down 2.7%

Shares of NYSE:LLY opened at $1,146.90 on Tuesday. The company’s fifty day moving average is $1,122.49 and its two-hundred day moving average is $1,036.98. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45. The stock has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 40.74, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.During the same quarter last year, the business posted $3.34 EPS. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 34.55 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.